Modality
ASO
MOA
PARPi
Target
TROP-2
Pathway
JAK/STAT
CF
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Nov 2031
Phase 1Current
NCT06571646
83 pts·CF
2022-12→2031-11·Recruiting
NCT08773286
927 pts·CF
2021-08→2028-04·Recruiting
1,010 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-085mo agoPDUFA· CF
2028-04-252.1y awayPh2 Data· CF
2031-11-175.6y awayPh2 Data· CF
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
PDUFA
2025-11-08 · 5mo ago
CF
Ph2 Data
2028-04-25 · 2.1y away
CF
Ph2 Data
2031-11-17 · 5.6y away
CF
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06571646 | Phase 1/2 | CF | Recruiting | 83 | PASI75 |
| NCT08773286 | Phase 1/2 | CF | Recruiting | 927 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |